Progesterone altering drug could reduce risk of aggressive breast cancer

New research co-led by UCL scientists has found that existing drugs known to modify the effect of the hormone progesterone, such as mifepristone, could reduce the risk of aggressive ‘triple negative’ breast cancer in women with an alteration of the BRCA1 gene. Lead author Professor Martin Widschwendter (UCL EGA Institute for Women’s Health).
Read: Telegraph (£), More: Sky News, Belfast Live, Wales Online, Bloomberg, UCL News